Concall Intelligence
Follow the Sept 2026 quarter results season by comparing what companies reported with what management said next. Search official call evidence, measurable guidance, changing outlook, operating risks, and prior commitments without treating commentary as a trading recommendation.
Management evidence
Generated 22 Oct, 11:10 am IST · click a summary to inspect source-linked evidence for this results quarter.
| Company | Call and sources | Reported result | Management outlook | Evidence-led conclusion | Review |
|---|---|---|---|---|---|
| METROBRAND Metro Brands Limited Consumer · Small | Sept 2026 5 Oct 2026 Transcript verified | Good 55/100 | Optimistic outlook No comparable prior call No measurable guidance | Metro Brands Limited reported steady operational performance for FY25-26, crossing the 1,000-store milestone and posting double-digit revenue and PAT growth, though shareholders raised concerns regarding a decline in revenue per square foot and return on capital employed. Evidence summary ready | |
| ALLCARGO Allcargo Logistics Limited Services · Small | Sept 2026 3 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance maintained | Allcargo Logistics reported a purposeful transformation year in FY2025-26, integrating express distribution and contract logistics under Vision 2030, resulting in revenue of INR 2,058 crores and a 16% growth in EBITDA to INR 233 crores. Evidence summary ready | |
| PAKKA PAKKA LIMITED Industrials · Small | Sept 2026 2 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance maintained | Pakka Limited held its 46th AGM reflecting on a demanding FY 2025-26 marked by operational shutdowns, equipment breakdowns, project delays, and lower earnings, while pointing to an improving June quarter and ongoing progress on Project Jagriti for long-term growth. Evidence summary ready | |
| SYMBIOTEC Symbiotec Pharmalab Limited Pharma · Micro | Sep 2026 2 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance maintained | Symbiotec Pharmalab reported Q1 FY27 consolidated revenue of INR 218 crores (up 7% YoY), driven mainly by the stable steroid API business. However, consolidated net profit stood lower at INR 14 crores due to a significant operational expense drag of INR 23 crores and depreciation of INR 11 crores from recently invested new businesses (biotech CDMO and complex injectables) where commercial revenues are yet to commence. Management maintains a confident revenue and EBITDA growth Evidence summary ready | |
| LICHSGFIN LIC Housing Finance Limited Financial Services · Mid | Sept 2026 1 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance maintained | LIC Housing Finance Limited reported record performance in FY 2025-26 with a loan book of Rs 320,707 crore and PAT of Rs 5,595 crore, driven by synergy across operations, cost management, and declining cost of funds. Management guided towards sustainable double-digit growth and margin protection via product diversification into LAP and LRD, while acknowledging legacy asset quality challenges and intense competition from banks. Evidence summary ready |